Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
106 hedge funds and large institutions have $80.4M invested in Sanofi Contingent Value Rights in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
6% more capital invested
Capital invested by funds: $76.1M → $80.4M (+$4.28M)
0% more funds holding
Funds holding: 106 → 106 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$448K |
| 2 |
DAM
DLD Asset Management
New York
|
+$322K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$27.1K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$14.5K |
| 5 |
NGA
New Generation Advisors
Manchester,
Massachusetts
|
+$13.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Pomelo Capital
New York
|
-$683K |
| 2 |
GCM
Gruss Capital Management
New York
|
-$490K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$141K |
| 4 |
JGC
J. Goldman & Co
New York
|
-$101K |
| 5 |
CL
CSS LLC
Chicago,
Illinois
|
-$58K |
GCVRZ Hedge Fund Activity: Q3 2018 in Review
106 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2018, worth a combined $80.4M — up 5.6% from $76.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GCVRZ positions and 9 closed out — a net gain of 1 holder — while 14 added to existing stakes and 19 trimmed.
The largest buyer was Highbridge Capital Management, adding an estimated $448K. The largest seller was Pomelo Capital, exiting entirely with an estimated $683K sold.
- 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $80.4M of Sanofi Contingent Value Rights stock for Q3 2018, up 5.6% quarter-over-quarter.
- 10 funds opened new Sanofi Contingent Value Rights positions in Q3 2018 and 9 closed out, a net change of +1 holder.
- The largest Sanofi Contingent Value Rights buyer in Q3 2018 was Highbridge Capital Management, an estimated $448K added.
- The largest Sanofi Contingent Value Rights seller in Q3 2018 was Pomelo Capital, an estimated $683K sold.
Based on aggregated 13F filings for Q3 2018.